

II. CLAIMS

1. (Currently Amended) A polynucleotide directed towards a gene of a catalytic subunit of human telomerase, wherein the polynucleotide specifically binds with the mRNA of the catalytic subunit of human telomerase in a target sequence region selected from the group consisting of region 2206-2225 (SEQ. ID NO 4) and region 2331-2350 (SEQ. ID NO 8), inhibits human telomerase expression and where the polynucleotide is an antisense oligonucleotide complementary to the target sequence region and is selected from the group consisting of SEQ ID NO 10 and SEQ ID NO 13.
2. (Currently Amended) The polynucleotide according to claim 1, wherein the polynucleotide consists ~~contains a oligonucleotide sequence selected from the group consisting~~ of SEQ ID NO 10 and SEQ ID NO 13.
3. Cancelled
4. (Previously Presented) The polynucleotide according to claim 1, wherein the polynucleotide is immobilized on a carrier selected from the group consisting of porous gels, aluminum oxide, bentonite, agarose, starch, nylon and polyacrylamide.
- 5-7. Cancelled

8. (Previously Presented) The polynucleotide according to claim 1, wherein the antisense oligonucleotide is modified by phosphothioate bonds.
9. Cancelled
10. (Previously Presented) A composition comprising a polynucleotide according to claim 1 in combination with a pharmaceutically tolerable carrier.
11. (Previously Presented) A kit comprising: a polynucleotide according to claim 1 and a pharmaceutically tolerable carrier.
12. Cancelled
13. (Withdrawn) Method for diagnosis, prophylaxis, therapy, follow-up and/or aftercare of diseases associated with cell growth, differentiation and/or division, comprising using a polynucleotide according to claim 1, optionally in combination with a pharmaceutically tolerable carrier.
14. (Withdrawn) The method according to the preceding claim, wherein the disease is a tumor.
15. (Withdrawn) The method according to claim 14, wherein the tumor is a solid tumor or a leukemia.
16. (Withdrawn) The method according to claim 15, wherein the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.

17. Canceled.
18. Canceled.
19. (Withdrawn) The method according to claim 16,
wherein the tumor of the urogenital tract is a
bladder carcinoma and/or a metastase of said tumor.
20. (Withdrawn) The method according to claim 13,
wherein the follow-up is monitoring the
effectiveness of an anti-tumor treatment.
21. (Withdrawn) The method according to claim~~s~~ 13
wherein the polynucleotide is used in a combination
therapy.
22. Canceled.
23. (Withdrawn) The method according to claim 22,
wherein the combination therapy comprises an
adjuvant biologically specified form of therapy.
24. (Withdrawn) The method according to claim 23,
wherein said form of therapy is an immune therapy.
25. (Withdrawn) The method according to claim~~s~~ 21,
wherein the combination therapy is a gene therapy
and/or a therapy using a polynucleotide against the
same or other target molecule.
26. (Withdrawn) The method according to claim~~s~~ 13 for

increasing the sensitivity of tumor cells to
cytostatic agents and/or radiation.

27. (Withdrawn) Method for inhibiting the vitality,
the proliferation rate of cells, for inducing
apoptosis and/or cell cycle arrest comprising the
step of using a polynucleotide according to claim 1.
28. (Previously Presented) A polynucleotide directed
towards a gene of a catalytic subunit of human
telomerase, wherein the polynucleotide specifically
binds with the mRNA of the catalytic subunit of
human telomerase in a target sequence consisting of
region 2206-2225 (SEQ. ID NO 4), inhibits human
telomerase expression and where the polynucleotide
is an antisense oligonucleotide complementary to the
target sequence region consisting of SEQ ID NO 10.
29. Cancelled
30. (Previously Presented) A polynucleotide directed
towards a gene of a catalytic subunit of human
telomerase, wherein the polynucleotide specifically
binds with the mRNA of the catalytic subunit of
human telomerase in a target sequence region
consisting of region 2331-2350 (SEQ. ID NO 8),
inhibits human telomerase expression and where the
polynucleotide is an antisense oligonucleotide
complementary to the target sequence region
consisting of SEQ ID NO 13.
31. Cancelled

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By /Serle Ian Mosof/
Serle Ian Mosoff
Attorney for Applicant(s)
Reg. No. 25,900

875 Third Avenue - 18th Floor
New York, New York 10022
Phone: (212) 808-0700
Fax: (212) 808-0844